

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following drug descriptions reflects the mechanism of action of sevabertinib?
 - a. Bispecific antibody binding to 2 distinct sites on HER2
 - b. PD-1/CTLA-4 bispecific antibody
 - c. HER2-directed antibody-drug conjugate
 - d. Dual EGFR/HER2 inhibitor
2. What is the target of ifinatamab deruxtecan?
 - a. HER2
 - b. HER3
 - c. TROP2
 - d. B7-H3
3. Which of the following drug types reflects the mechanism of action of neladalkib?
 - a. EGFR/MET bispecific antibody
 - b. ALK inhibitor
 - c. HER3-directed antibody-drug conjugate
 - d. ROS1 inhibitor
4. Which of the following drug types reflects the mechanism of action of zidesamtinib?
 - a. EGFR/MET bispecific antibody
 - b. ALK inhibitor
 - c. HER3-directed antibody-drug conjugate
 - d. ROS1 inhibitor
5. Which of the following statements best describes outcomes with fixed-duration first-line acalabrutinib and venetoclax with or without obinutuzumab, in comparison to chemoimmunotherapy, in the Phase III AMPLIFY trial for patients with chronic lymphocytic leukemia?
 - a. Progression-free survival (PFS) was improved with acalabrutinib/venetoclax/obinutuzumab but not with acalabrutinib/venetoclax
 - b. PFS was improved with both acalabrutinib/venetoclax and acalabrutinib/venetoclax/obinutuzumab, but rates of hypertension and atrial arrhythmias were high
 - c. PFS was improved with both acalabrutinib/venetoclax and acalabrutinib/venetoclax/obinutuzumab with manageable tolerability profiles
6. Emerging results from the Phase III BRUIN CLL-314 study evaluating pirtobrutinib versus ibrutinib for patients with treatment-naïve or pretreated, Bruton tyrosine kinase inhibitor-naïve CLL include which efficacy finding?
 - a. A statistically significant improvement in PFS with pirtobrutinib
 - b. Noninferiority in overall response rate (ORR) with pirtobrutinib in both the pretreated and intent-to-treat populations
 - c. Noninferiority in ORR with pirtobrutinib in the pretreated population only

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

7. Which of the following drug types reflects the mechanism of action of relacorilant?
 - a. CDH6-directed antibody-drug conjugate
 - b. PD-1/CTLA-4 bispecific antibody
 - c. Selective glucocorticoid receptor antagonist
 - d. WEE1 inhibitor
8. What was the approximate objective response rate with raludotatug deruxtecan for patients with platinum-resistant advanced ovarian cancer across all doses evaluated in the Phase II dose-optimization part of the ongoing Phase II/III REJOICE-Ovarian01 study?
 - a. 15%
 - b. 25%
 - c. 50%
 - d. 85%
9. The bispecific antibody zanidatamab binds to which of the following targets?
 - a. HER2 and CD8
 - b. HER2 and HER3
 - c. HER2 and FGFR2
 - d. Two distinct HER2 domains
10. In a Phase II study of first-line zanidatamab with chemotherapy for HER2-positive advanced gastroesophageal adenocarcinoma, what was the approximate objective response rate for all patients?
 - a. 12%
 - b. 25%
 - c. 52%
 - d. 76%
 - e. 100%